Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Linde PLC (LIN) vs New York Times Co (NYT) Price & Performance

New York Times CoTrade

Price performance (Past 24H)

Key statistics

Linde PLC vs New York Times Co — how do they compare? Linde PLC trades at $484.71 (market cap $222.05B), while New York Times Co trades at $66.38 (market cap $10.74B). The key difference: Linde PLC is far larger — about 20.7× New York Times Co's market cap, and New York Times Co pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and New York Times Co for 81 Days on average.

LINNYT
Market Cap
$222.05B$10.74B
Volume
2,116,4402,096,352
Sector
Basic MaterialsMedia
52-Week High
$546.64$85.86
52-Week Low
$389.38$54.66
Typical Hold Time
88 Days81 Days
Enterprise Value
$245.17B$10.14B
Dividend Yield
1.33%1.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Linde PLC

LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.

The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.

New York Times Co

The New York Times Company (NYSE: NYT) trades at $65.64, up 1.14% today, with a bullish technical signal and strong fundamentals. Revenue grew from $2.3B in 2022 to $2.8B in 2025, with net income margin expanding to 12.17%. Recent earnings beats and a declared $0.23 dividend highlight operational strength, though a shareholder lawsuit presents headline risk.

Outlook is positive given consistent earnings outperformance and analyst consensus target of $84.00, implying 28% upside. Key risks include the pending lawsuit's impact on reputation and competitive pressures in digital media. Cash flow generation remains robust, supporting dividend sustainability and growth initiatives.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LIN
0% Buy100% Sell
Avg holding period · 88 Days
NYT
13% Buy87% Sell
Avg holding period · 81 Days

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN →

About New York Times Co

New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.

Read more on NYT →